|Hesperetin Liposomes for Cancer Therapy|
|Wolfram, J; Scott, B; Boom, K; Shen, JL; Borsoi, C; Suri, K; Grande, R; Fresta, M; Celia, C; Zhao, YL; Shen, H; Ferrari, M; Zhao YL(赵宇亮)
|发表期刊||CURRENT DRUG DELIVERY
|摘要||Hesperetin is a compound from citrus fruit that has previously been found to exert anticancer activity through a variety of mechanisms. However, the application of hesperetin to cancer therapy has been hampered by its hydrophobicity, necessitating the use of toxic solubilizing agents. Here, we have developed the first liposome-based delivery system for hesperetin. Liposomes were fabricated using the thin-layer evaporation technique and physical and pharmacological parameters were measured. The liposomes remained stable for prolonged periods of time in serum and under storage conditions, and displayed anticancer efficacy in both H441 lung cancer cells and MDA-MB-231 breast cancer cells. Furthermore, the anticancer activity was not impaired in cells expressing the multidrug resistance protein 1 (MDR-1). In conclusion, the encapsulation of hesperetin in liposomes does not interfere with therapeutic efficacy and provides a biocompatible alternative to toxic solubilizing agents, thereby enabling future clinical use of this compound for cancer therapy.|
; MACROMOLECULAR THERAPEUTICS
|WOS类目||Pharmacology & Pharmacy
Wolfram, J,Scott, B,Boom, K,et al. Hesperetin Liposomes for Cancer Therapy[J]. CURRENT DRUG DELIVERY,2016,13(5):711-719.
Wolfram, J.,Scott, B.,Boom, K.,Shen, JL.,Borsoi, C.,...&赵宇亮.(2016).Hesperetin Liposomes for Cancer Therapy.CURRENT DRUG DELIVERY,13(5),711-719.
Wolfram, J,et al."Hesperetin Liposomes for Cancer Therapy".CURRENT DRUG DELIVERY 13.5(2016):711-719.